Search - tctmd.com

Displaying 461 - 480 of 671

Sort: Relevancy | Date

Presentation

Heparin vs. Bivalirudin in Patients with NSTE-ACS Undergoing PCI

Presenter: Oskar Anger?s

May 23, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Presenter: Paul A. Gurbel

May 03, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

Presenter: Stavros Spiliopoulos

April 25, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Presenter: Siddharth A. Wayangankar

April 19, 2013

Presentation Fellows 2013

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Presenter: Matthew Price

April 16, 2013

Presentation Fellows 2013

Antiplatelet Therapy for the Interventionalist

Presenter: Matthew Price

April 16, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Presentation

Post ACC Wrap-up CHAMPION PHOENIX and STREAM

Presenter: Gregg W. Stone

March 29, 2013

Presentation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Presenter: T.B. Larsen

March 29, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Presentation

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg W. Stone

March 26, 2013

Presentation

CHAMPION PHOENIX

Presenter: Deepak L. Bhatt

March 09, 2013

Presentation ACC 2013

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Presenter: Giuseppe Patti

March 08, 2013

Presentation PCI Outcomes 2013

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Presenter: Dominick J. Angiolillo

March 07, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation

Preprocedural Estimate of Individualized Bleeding Risk Impacts Physicians’ Bivalirudin Use During PCI

Presenter: S. C. Rao

March 05, 2013

Advertisement

Heparin vs. Bivalirudin in Patients with NSTE-ACS Undergoing PCI

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

PARADOX: Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS

Platelet Function Testing, Genomics, and Antiplatelet Agent Resistance

Antiplatelet Therapy for the Interventionalist

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Post ACC Wrap-up CHAMPION PHOENIX and STREAM

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

CHAMPION PHOENIX

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Preprocedural Estimate of Individualized Bleeding Risk Impacts Physicians’ Bivalirudin Use During PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content